ASCO–SSO guidelines recommend considering BRCA1/2 germline pathogenic variants testing for all individuals diagnosed with BC up to the age of 65, with selective testing for those above 65 based on personal and family history as well as ancestry (24). Here, BRCA1 is linked to breast cancer.